2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial

Aron Goldhirsch, Richard D. Gelber, Martine J. Piccart-Gebhart, Evandro De Azambuja, Marion Procter, Thomas M. Suter, Christian Jackisch, David Cameron, Harald A. Weber, Dominik Heinzmann, Lissandra Dal Lago, Eleanor McFadden, Mitch Dowsett, Michael Untch, Luca Gianni, Richard Bell, Claus Henning Köhne, Anita Vindevoghel, Michael Andersson, A. Murray BruntDouglas Otero-Reyes, Santai Song, Ian Smith, Brian Leyland-Jones, Jose Baselga

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of '2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial'. Together they form a unique fingerprint.

Medicine & Life Sciences